July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
The Treatment Effect of 0.1% Tacrolimus Eye Drops in Young and Elder Vernal Keratoconjunctivitis Patients
Author Affiliations & Notes
  • Keiko Yokoi
    Ophtalmology, Kyoto Prefectural University of Medicin, Kyoto, Japan
  • Norihiko Yokoi
    Ophtalmology, Kyoto Prefectural University of Medicin, Kyoto, Japan
  • Mayumi Ueta
    Ophtalmology, Kyoto Prefectural University of Medicin, Kyoto, Japan
  • Chie Sotozono
    Ophtalmology, Kyoto Prefectural University of Medicin, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Keiko Yokoi, None; Norihiko Yokoi, None; Mayumi Ueta, None; Chie Sotozono, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6713. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Keiko Yokoi, Norihiko Yokoi, Mayumi Ueta, Chie Sotozono; The Treatment Effect of 0.1% Tacrolimus Eye Drops in Young and Elder Vernal Keratoconjunctivitis Patients. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6713.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although vernal keratoconjunctivitis (VKC) is known to be self-limiting and become milder with age, it can sometimes occur in elderly subjects. In this retrospective study, we investigated the effect of 0.1% tacrolimus (TL) eye drops in young and elder VKC patients.

Methods : In this study, 8 eyes of 8 young VKC patients [7 males, 1 female; mean age: 9.1±1.0 (SD) years] treated with TL (twice daily) in addition to the baseline treatment with or without topical steroid were compared with 8 eyes from 8 age-matched male VKC patients (mean age: 8.5±0.8 years) treated with baseline treatment only. In those patients, improvement of subjective symptoms (SSs) including itching, discharge, lacrimation, sensitivity to light, foreign body sensation, and eye pain, and objective findings (OFs) including redness and swelling of bulbar or palpebral conjunctiva, follicle, papilla, giant papilla, Trantas dots and/or thickening of limbus, and corneal epithelial damage, each graded from 0 to 3 (0=none, 1, 2, and 3=mild, moderate, and severe), were assessed before and at 1, 3, 6, 9, 12, 18 months post treatment. In 5 elder male VKC patients (mean age: 42.6±5.0 years), the treatment effect was compared between 18 months before and after starting TL in addition to the baseline treatment.

Results : In young VKC patients treated with TL, significant improvement was seen in both SSs and OFs (SSs: OFs) until 6-months post treatment (0.8±1.5; 7.9±2.7) (p<0.05), followed by mild improvement with decreased use of topical steroid until at 18 months compared to before the TL treatment (7.0±7.2; 11.2±2.8). However, 8 younger VKC patients treated without TL showed variable improvement in SSs and OFs, with no significant improvement at 6 months (9.0±4.6; 14.0±4.7) post treatment compared to that before treatment (10.6±6.0; 16.8±2.1). In elder VKC patients, significant improvement was seen in SSs and OFs at 6-months post TL treatment (0.8±0.8; 6.6±3.3) compared with that before treatment (12.0±6.6; 12.2±3.1), followed by stable improvement until at 18 months. However, those patients showed no significant improvement for 18 months before starting TL treatment.

Conclusions : We found 0.1 % tacrolimus eye drops to be effective in both young and elder patients with VKC.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×